Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Mirati Therapeutics Inc.
Scientific Title
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab Plus Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation